Shasqi

About

Shasqi, Inc. is a clinical-stage biotechnology company based in San Francisco, California, founded in 2015. The company specializes in precision oncology therapeutics through its proprietary Click Activated Protodrugs Against Cancer (CAPAC™) platform. This innovative platform utilizes click chemistry to enable pre-targeting, allowing for the delivery of cancer drugs directly to tumors while minimizing systemic toxicity. Shasqi is pioneering the use of click chemistry in human applications, building on advancements in antibody-drug conjugates. The company has developed a robust pipeline, including its lead asset SQ3370, which is in Phase 1/2 trials for advanced malignant solid tumors. Shasqi actively collaborates with biopharmaceutical partners to expand its CAPAC library and enhance its tumor-targeting capabilities. With a dedicated team and significant funding, Shasqi is positioned to make impactful contributions to cancer therapy.